Physician profile
Roger C Yang
NPI 1295849883
$14,444.58
in general payments reported to CMS, 2019-2025
20 companies · $938 in 2025
The $938 reported for 2025 was more than what 95% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $72.49 · 2021: $422 · 2022: $390 · 2023: $6,401 · 2024: $5,330 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,530 · Food and Beverage: $2,904 · Travel and Lodging: $2,199 · Education: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,530.00 |
| Food and Beverage | $2,903.51 |
| Travel and Lodging | $2,198.73 |
| Education | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $10,587.05 | 2022-2025 | Veklury, Yeztugo |
| Teleflex LLC | $817.69 | 2020-2024 | Quikclot, Arrow, Airtraq Video Laryngoscope Camera |
| Astrazeneca Pharmaceuticals LP | $543.33 | 2019-2024 | Andexxa, Farxiga |
| Vertex Pharmaceuticals Incorporated | $422.94 | 2025 | |
| Melinta Therapeutics, LLC | $304.68 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $242.93 | 2023-2025 | Giapreza |
| Mallinckrodt Hospital Products INC. | $192.42 | 2024 | Terlivaz |
| Medtronic, INC. | $152.42 | 2024 | Micra |
| Portola Pharmaceuticals, LLC | $152.12 | 2019 | |
| Haemonetics Corporation | $148.08 | 2021-2025 | Teg6s Hemostasis System |
| Csl Behring | $147.21 | 2019 | |
| Alkermes, INC. | $124.88 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.09 | 2025 | Lifevest |
| Mallinckrodt Enterprises LLC | $121.87 | 2019 | |
| Idorsia Pharmaceuticals US INC | $120.52 | 2023 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Z-Medica, LLC | $71.75 | 2019-2020 | |
| Heron Therapeutics, INC. | $65.89 | 2022 | |
| Bard Access Systems, INC. | $47.24 | 2021 | |
| Getinge USA Sales, LLC | $32.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.